Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T64244 | CDK4/6-IN-10 | ||
CDK4/6-IN-10 是一种选择性的、有效的、口服具有活力的 CDK4 (IC50: 22 nM) 和 CDK6 (IC50: 10 nM) 抑制剂,具有抗肿瘤效果。CDK4/6-IN-10 具有潜力进行多发性骨髓瘤 (MM) 的研究。 | |||
T72951 |
CDK4/6-IN-14
|
||
CDK4/6-IN-14 是一种有效且高度选择性的 CDK4和 CDK6(CDK) 抑制剂,IC50分别为 10 nM 和 16 nM。CDK4/6-IN-14 的选择性是 CDK1、2、7 和 9 的 60 多倍,并且在其他 205 种激酶中表现出高选择性。 | |||
T62192 |
CDK4/6-IN-9
|
||
CDK4/6-IN-9 (compound 10) 是一种 CDK4/6 的选择性抑制剂,能够作用于 CDK6/cyclin D1 (IC50: 905 nM)。CDK4/6-IN-9 对多发性骨髓瘤 (MM) 具有潜在的研究价值。 | |||
T79112 |
CDK4/6-IN-17
|
CDK | Cell Cycle/Checkpoint |
CDK4/6-IN-17(compound 12)为具有口服活性的CDK4/6抑制剂,在BE(2)细胞的IC50为10-100 nM。CDK4/6-IN-17在COLO205异种移植模型中有效抑制肿瘤生长。 | |||
T69196 |
AG-012986
|
||
AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activities in vitro with IC(50)s of <100 nmol/L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 also showed dose-dependent retinoblastoma Ser(795) hy... | |||
T69197 |
AG-012986 HCl
|
||
AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative activities in vitro with IC(50)s of <100 nmol/L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 HCl was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 HCl also showed dose-dependent retinoblas... |